ES2196592T3 - Acidos alcanohidroxamicos sustituidos y metodo para reducir el nivel de tnf-alfa. - Google Patents

Acidos alcanohidroxamicos sustituidos y metodo para reducir el nivel de tnf-alfa.

Info

Publication number
ES2196592T3
ES2196592T3 ES98938151T ES98938151T ES2196592T3 ES 2196592 T3 ES2196592 T3 ES 2196592T3 ES 98938151 T ES98938151 T ES 98938151T ES 98938151 T ES98938151 T ES 98938151T ES 2196592 T3 ES2196592 T3 ES 2196592T3
Authority
ES
Spain
Prior art keywords
carbon atoms
alkyl
hydrogen
carbopropoxy
carboethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98938151T
Other languages
English (en)
Inventor
George W Muller
Hon-Wah Man
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of ES2196592T3 publication Critical patent/ES2196592T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
    • C07D209/66—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles with oxygen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

Un derivado de ácido hidroxámico, elegido entre el grupo formado por (a) compuestos de la **fórmula** en la que cada uno de R1 y R2, tomados con independencia entre sí, es hidrógeno o alquilo de 1 a 8 átomos de carbono, o bien R1 y R2, tomados juntos, junto con los átomos de carbono dibujados, que los unen, son o-fenileno, o-naftileno o ciclohexeno-1, 2-diilo, sin sustituir o sustituidos de 1 a 4 veces por sustituyentes elegidos con independencia entre sí entre nitro, ciano, trifluormetilo, carboetoxi, carbometoxi, carbopropoxi, acetilo, carbamoílo, acetoxi, carboxi, hidroxi, amino, alquilamino de 1 a 8 átomos de carbono, dialquilamino de 1 a 8 átomos de carbono, acilamino de 1 a 8 átomos de carbono, alquilo de 1 a 10 átomos de carbono, alcoxi de 1 a 10 átomos de carbono, y halógeno; R3 es fenilo sustituido de una a cuatro veces por sustituyentes, cada uno de ellos elegido con independencia entre sí entre nitro, ciano, trifluormetilo, carboetoxi, carbometoxi, carbopropoxi, acetilo, carbamoílo, acetoxi, carboxi, hidroxi, amino, alquilo de 1 a 10 átomos de carbono, alcoxi de 1 a 10 átomos de carbono, cicloalcoxi de 3 a 6 atomos de carbono, cicloalquilidenometilo C4-C6, alquilideno metilo C3-C10, indaniloxi y halógeno; R4 es hidrógeno, alquilo de 1 a 10 átomos de carbono, fenilo o bencilo; R4'' es hidrógeno o alquilo de 1 a 6 átomos de carbono; R5 es -CH2-, -CH2-CO-, -CO-, -SO2-, -S- o -NHCO-; y n es el número 0, 1 ó 2; y (b) las sales de adición de ácido de dichos compuestos que contienen un átomo de nitrógeno susceptible de proto narse; con la condición de que el compuesto sea distinto de la (4-metoxifenil)--ftalimido-N-metoxiacetamida.
ES98938151T 1997-07-31 1998-07-30 Acidos alcanohidroxamicos sustituidos y metodo para reducir el nivel de tnf-alfa. Expired - Lifetime ES2196592T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90397597A 1997-07-31 1997-07-31

Publications (1)

Publication Number Publication Date
ES2196592T3 true ES2196592T3 (es) 2003-12-16

Family

ID=25418328

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98938151T Expired - Lifetime ES2196592T3 (es) 1997-07-31 1998-07-30 Acidos alcanohidroxamicos sustituidos y metodo para reducir el nivel de tnf-alfa.

Country Status (20)

Country Link
US (3) US6214857B1 (es)
EP (1) EP1035848B1 (es)
JP (1) JP2001511448A (es)
KR (1) KR100716475B1 (es)
CN (1) CN1265590A (es)
AT (1) ATE238052T1 (es)
AU (1) AU737008B2 (es)
BR (1) BR9815895A (es)
CA (1) CA2295295A1 (es)
CZ (1) CZ299873B6 (es)
DE (1) DE69813876T2 (es)
ES (1) ES2196592T3 (es)
FI (1) FI119841B (es)
HU (1) HUP0003761A3 (es)
NO (1) NO315043B1 (es)
NZ (1) NZ502379A (es)
PT (1) PT1035848E (es)
RU (1) RU2199530C2 (es)
TR (1) TR200000221T2 (es)
WO (1) WO1999006041A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US6518281B2 (en) * 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
KR100539030B1 (ko) * 1996-08-12 2005-12-27 셀진 코포레이션 면역치료제 및 이를 이용하여 사이토카인 농도를 감소시키는 방법
ES2196592T3 (es) * 1997-07-31 2003-12-16 Celgene Corp Acidos alcanohidroxamicos sustituidos y metodo para reducir el nivel de tnf-alfa.
CA2319173A1 (en) * 1998-02-11 1999-08-19 Jingwu Duan Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
DE122010000047I1 (de) 2001-06-26 2011-05-05 Amgen Fremont Inc Antikörper gegen opgl
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
MXPA04009996A (es) 2002-04-12 2005-07-01 Celgene Corp Metodos para la identificacion de moduladores de la angiogenesis, compuestos descubiertos por los mismos, y metodos de tratamiento usando los compuestos.
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
AU2003234624B8 (en) * 2002-05-17 2009-03-12 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
AU2003250482A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
US7842691B2 (en) * 2002-10-15 2010-11-30 Celgene Corporation Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
WO2004041181A2 (en) * 2002-10-31 2004-05-21 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US20060165649A1 (en) * 2002-11-06 2006-07-27 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
CA2505131A1 (en) 2002-11-06 2004-05-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
BR0316256A (pt) * 2002-11-18 2005-10-04 Celgene Corp Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
JP2006510617A (ja) * 2002-11-18 2006-03-30 セルジーン・コーポレーション （＋）−３−（３，４−ジメトキシ−フェニル）−３−（１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−プロピオンアミドの使用方法およびそれを含む組成物
ZA200505308B (en) 2002-12-30 2006-10-25 Celgene Corp Fluoroalkoxy-substituted 1, 3-Dihydro-Isoindolyl compounds and their pharmaceutical uses
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
JP2006519875A (ja) * 2003-03-06 2006-08-31 セルジーン・コーポレーション 中枢神経系障害を治療するための選択的サイトカイン阻害剤
JP4713465B2 (ja) * 2003-03-12 2011-06-29 セルジーン コーポレイション ７−アミド−イソインドリル化合物およびその薬学的使用
CN100427465C (zh) * 2003-03-12 2008-10-22 细胞基因公司 N-烷基-异羟肟酸-异吲哚基化合物及其药物用途
WO2004080422A2 (en) * 2003-03-12 2004-09-23 Celgene Corporation N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
DE10340739A1 (de) * 2003-09-04 2005-04-07 Satia Gmbh Verfahren zur enzymatischen Herstellung von Mono- und Diacylglycerid-haltigen Emulgatoren
CA2543132A1 (en) * 2003-10-23 2005-05-19 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
US20080213213A1 (en) * 2004-04-14 2008-09-04 Zeldis Jerome B Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
WO2005102317A1 (en) * 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
WO2005112917A1 (en) * 2004-05-05 2005-12-01 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
EP1750697A4 (en) * 2004-05-05 2009-08-26 Celgene Corp METHODS AND COMPOSITIONS USING CYTOKINE INHIBITION DRUGS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
US7405237B2 (en) 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
JP2008518924A (ja) * 2004-10-28 2008-06-05 セルジーン・コーポレーション 中枢神経系損傷の治療及び管理のためのｐｄｅ４モジュレータを使用する方法及び組成物
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
EP2049120A4 (en) 2006-07-31 2011-09-07 Janssen Pharmaceutica Nv UROTENSIN II RECEPTOR ANTAGONISTS
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
PA8782701A1 (es) * 2007-06-07 2009-01-23 Janssen Pharmaceutica Nv Antagonistas del receptor de urotensina ii
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
CA2732762A1 (en) * 2008-08-02 2010-02-11 William A. Kinney Urotensin ii receptor antagonists
BRPI0918055A2 (pt) 2008-09-02 2015-12-01 Addex Pharmaceuticals Sa derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato.
CN102232074B (zh) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
JP2012517441A (ja) 2009-02-10 2012-08-02 セルジーン コーポレイション 結核の治療、予防及び管理のためのｐｄｅ４モジュレーターの使用法及び含有組成物
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
ME01573B (me) 2009-05-12 2014-09-20 Addex Pharma Sa DERIVATI 1,2,4-TRIAZOLO[4,3-a]PIRIDINA I NJIHOVA UPOTREBA U TRETMANU ILI PREVENCIJI NEUROLOŠKIH I PSIHIJATRIJSKIH POREMEĆAJA
MX341050B (es) 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
AU2011268450B2 (en) 2010-06-15 2015-07-16 Amgen (Europe) GmbH Biomarkers for the treatment of psoriasis
WO2012062751A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
CN102976974B (zh) * 2012-12-29 2015-01-21 吉首大学 苯基苄基丙酰-n-甲基氧肟酸类尿素酶抑制剂及其合成和用途
CN102993153B (zh) * 2012-12-29 2015-05-13 吉首大学 异黄酮-n-甲基氧肟酸类尿素酶抑制剂及其合成和用途
CN102993152B (zh) * 2012-12-29 2015-04-01 吉首大学 尿素酶抑制剂异黄酮氧肟酸化合物及其合成和用途
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
LT3096790T (lt) 2014-01-21 2019-10-10 Janssen Pharmaceutica, N.V. Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
SI3431106T1 (sl) 2014-01-21 2021-03-31 Janssen Pharmaceutica Nv Kombinacije, ki vsebujejo pozitivne alosterične modulatorje metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba
US20170087129A1 (en) 2014-05-16 2017-03-30 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
MX2016014384A (es) 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
WO2017030892A1 (en) 2015-08-14 2017-02-23 Reaction Biology Corp. Histone deacetylase inhibitors and methods for use thereof
US10682336B2 (en) 2015-10-21 2020-06-16 Amgen Inc. PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)
KR102445637B1 (ko) * 2017-11-28 2022-09-22 솔브레인 주식회사 레벨링제 및 이를 포함하는 전기도금 조성물
CN110386893A (zh) * 2018-04-17 2019-10-29 天津合美医药科技有限公司 异吲哚衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077998A (en) * 1975-10-28 1978-03-07 Morton-Norwich Products, Inc. Phthaloyl amino acid hydroxamic acids
US4173652A (en) 1976-12-18 1979-11-06 Akzona Incorporated Pharmaceutical hydroxamic acid compositions and uses thereof
US4820828A (en) 1987-03-04 1989-04-11 Ortho Pharmaceutical Corporation Cinnamohydroxamic acids
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
NZ305940A (en) 1995-07-26 1999-05-28 Pfizer N-(aroyl)glycine hydroxamic acid derivatives and related compounds that inhibit the production of tnf and are useful in treating asthma
ES2196592T3 (es) * 1997-07-31 2003-12-16 Celgene Corp Acidos alcanohidroxamicos sustituidos y metodo para reducir el nivel de tnf-alfa.

Also Published As

Publication number Publication date
JP2001511448A (ja) 2001-08-14
US6656964B2 (en) 2003-12-02
EP1035848A4 (en) 2001-05-23
NZ502379A (en) 2002-10-25
ATE238052T1 (de) 2003-05-15
TR200000221T2 (tr) 2000-09-21
RU2199530C2 (ru) 2003-02-27
BR9815895A (pt) 2001-01-16
PT1035848E (pt) 2003-09-30
DE69813876T2 (de) 2004-01-29
HUP0003761A2 (en) 2001-03-28
NO996529D0 (no) 1999-12-28
AU8674198A (en) 1999-02-22
CZ299873B6 (cs) 2008-12-17
AU737008B2 (en) 2001-08-09
DE69813876D1 (de) 2003-05-28
FI119841B (fi) 2009-04-15
EP1035848A1 (en) 2000-09-20
KR20010022429A (ko) 2001-03-15
KR100716475B1 (ko) 2007-05-10
FI20000061A (fi) 2000-03-02
US20010049371A1 (en) 2001-12-06
NO315043B1 (no) 2003-06-30
US7091356B2 (en) 2006-08-15
CA2295295A1 (en) 1999-02-11
EP1035848B1 (en) 2003-04-23
US6214857B1 (en) 2001-04-10
US20040006096A1 (en) 2004-01-08
NO996529L (no) 2000-03-28
CZ2000256A3 (cs) 2000-06-14
WO1999006041A1 (en) 1999-02-11
CN1265590A (zh) 2000-09-06
HUP0003761A3 (en) 2001-04-28

Similar Documents

Publication Publication Date Title
ES2196592T3 (es) Acidos alcanohidroxamicos sustituidos y metodo para reducir el nivel de tnf-alfa.
RU97112858A (ru) Замещенные имиды в качестве ингибиторов
Hori et al. A novel protein phosphatase inhibitor, tautomycin Effect on smooth muscle
KR920008063A (ko) 전립선 이상비대 치료용 아자스테로이드 화합물, 그것의 제조방법 및 용도
ES2191611T3 (es) Compuesto bajo forma de isomero geometrico u optico puro o de mezcla de tales isomeros.
SE9401727D0 (sv) New compounds I
KR890000485A (ko) 캠프토데신 유도체 및 그의 아미노기에 있어서의 산 부가염 및 4급 암모늄염 및 그의 제조방법
CO4890849A1 (es) Cicloalcano-piridinas
RU97112857A (ru) Новые иммунотерапевтические ариламиды
AR010001A1 (es) Composiciones detergentes
KR880001597A (ko) 알킬렌디아민
PE74399A1 (es) Combinaciones para diabetes de sulfonilurea - glitazona
MX172925B (es) Composiciones de alkil fenol y compuesto de amino y aceites y combustibles de motor de dos ciclos que las contienen
PE20010634A1 (es) Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que las contienen
BR0108974A (pt) 3-fenil-5-alcóxi-1,3,4-oxdiazol-2-onas substituìdas e seu uso para a inibição das lipases sensìveis a hormÈnios
ES2094812T3 (es) Un procedimiento mejorado para la preparacion de derivados sustituidos de indolona.
CO4750652A1 (es) Derivados de azacicloalcanos, su preparacion y sus aplica- ciones en terapeutica
NO179574C (no) Hårfargemiddel samt tetrahydro-kinoksaliner
AR006301A1 (es) Derivados de oxazolidin-2-ona, procedimiento para prepararlos, medicamento constituido por dicho derivado y composicion farmaceutica que comprende a dicho derivado
CO4940417A1 (es) DERIVADOS DE 2,3-DIHIDROFURO[3,2-b]PIRIDINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
BR0302533A (pt) Misturas de corantes não-azo dispersos
CO4890850A1 (es) Derivados de 6-pirrolidin-2-ilpiridinas, su reparacion y preparacion en terapeutica.
ES2074980T3 (es) Aditivos para combustible mejorados.
PT84161B (pt) Processo para a preparacao de derivados de 3-acilaminometil-imidazo-{1,2-a}-piridinas e de composicoes farmaceuticas que os contem
BR0008951B1 (pt) corantes de azóxi e de complexo de cobre, processo para preparar corantes de complexo de cobre, método para usar um ou mais corantes de azóxi e/ou seus complexos de cobre, substratos naturais ou sintéticos, e precesso para preparar corantes de azóxi.